Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Nail-Patella Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Nail-Patella Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Lipoprotein Glomerulopathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Lipoprotein Glomerulopathy in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Glomerular disease Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Glomerular disease with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Glomerulonephritis, Membranoproliferative Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Glomerulonephritis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Glomerulonephritis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Glomerulonephritis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Balkan Nephropathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Balkan Nephropathy with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
proliferative nephritis unspecified Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate proliferative nephritis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Nephritis, Interstitial Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Nephritis, Interstitial in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Kidney Diseases Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Kidney Diseases with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Acute Tubulointerstitial Nephritis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Acute Tubulointerstitial in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Kidney Tubular Necrosis, Acute Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Kidney Tubular Necrosis, Acute in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Hemoptysis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hemoptysis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..